


SJF-0628

Cat. No.:	HY-136420
CAS No.:	2413035-41-1
Molecular Formula:	C ₅₁ H ₅₇ F ₂ N ₉ O ₇ S ₂
Molecular Weight:	1010.18
Target:	PROTACs; Raf
Pathway:	PROTAC; MAPK/ERK Pathway
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 160 mg/mL (158.39 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	0.9899 mL	4.9496 mL	9.8992 mL
				5 mM	0.1980 mL	0.9899 mL	1.9798 mL
				10 mM	0.0990 mL	0.4950 mL	0.9899 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 4 mg/mL (3.96 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 4 mg/mL (3.96 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	SJF-0628 (compound 512) is a PROTAC RAF degrader. SJF-0628 induces targeted degradation of BRAF mutants (DC ₅₀ : 5.4 nM, 4.64 nM, 15.5 nM, 2.11 nM, 63.9 nM for BRAF V600E, V600K, G464V, G469A, K601E respectively). SJF-0628 has anti-tumor activity. SJF-0628 can be used for research of disorders that result from aggregation or accumulation of RAF, or the constitutive activation of RAF ^[1] .
-------------	---

REFERENCES

- [1]. Andrew P. Crew, et al. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides. Patent. US 20200129627 A1.
- [2]. Chapdelaine AG, et al. The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA